Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice

ENDURANCE: Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Dutch Daily Clinical Practice. Part B1

This study uses existing cancer registry and health record data to understand how nivolumab is used in routine care in the Netherlands for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach.

Inclusion Criteria:

• Registered in the Netherlands Cancer Registry (NCR)
• Diagnosed with Esophageal Adenocarcinoma (EAC), Gastro-esophageal Junction Adenocarcinoma (GEJAC), or Gastric Adenocarcinoma (GAC) from 01-Aug-2022 to 31-Jul-2024
• Age ≥18 years at diagnosis
• Unresectable advanced (cT4B) or synchronous metastatic (cM1) disease at diagnosis
• (Cohort 2) Programmed cell Death Ligand 1 (PD-L1) CPS ≥5
• (Cohort 3) Received nivolumab as part of first-line treatment

Exclusion Criteria:

• Neuro-endocrine carcinomas or non-epithelial cancers of esophagus/ gastroesophageal junction /stomach
• Positive HER2 expression